Voluntary Scheme for Branded Medicines Pricing and Access

(asked on 10th January 2023) - View Source
Questioner
Laurence Robertson Portrait
Laurence Robertson
(Conservative - Tewkesbury)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential impact of changes to the Voluntary Scheme for Branded Medicines Pricing Access rebate on (a) investment in clinical trials and (b) the UK's market for launching innovative treatments.

Answered by
Will Quince Portrait
Will Quince
This question was answered on 16th January 2023

I refer the hon. Member to the answers given on 9 January 2023 to Question 113161, 113162, 113178.

Reticulating Splines